e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Burden and management of obstructive airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Estimates of the prevalence of alpha-1 antitrypsin deficiency PI*S and PI*Z alleles and the numbers at risk in Europe
B. Lara, I. Blanco, F. J. de Serres, M. Miravitlles, E. Fernandez-Bustillo (Barcelona, Asturias, Spain; Research Triangle Park, United States Of America)
Source:
Annual Congress 2005 - Burden and management of obstructive airway diseases
Session:
Burden and management of obstructive airway diseases
Session type:
Poster Discussion
Number:
1417
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Lara, I. Blanco, F. J. de Serres, M. Miravitlles, E. Fernandez-Bustillo (Barcelona, Asturias, Spain; Research Triangle Park, United States Of America). Estimates of the prevalence of alpha-1 antitrypsin deficiency PI*S and PI*Z alleles and the numbers at risk in Europe. Eur Respir J 2005; 26: Suppl. 49, 1417
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Estimated numbers and prevalence of PI*S and PI*Z alleles of α1-antitrypsin deficiency in European countries
Source: Eur Respir J 2006; 27: 77-84
Year: 2006
Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil
Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population
Year: 2013
Alpha
1
-antitrypsin deficiency-related PI*Z and PI*S alleles in a random sample of Polish population
Source: Eur Respir J 2006; 28: Suppl. 50, 453s
Year: 2006
The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes
Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020
Year: 2020
Estimated numbers and prevalence of PI*S and PI*Z deficiency alleles of α1-antitrypsin deficiency in Asia
Source: Eur Respir J 2006; 28: 1091-1099
Year: 2006
Rare alpha-1 antitrypsin mutations in the Irish population
Source: Annual Congress 2011 - Genetic and environmental risk factors for respiratory diseases
Year: 2011
Rare alpha-1 antitrypsin mutations in the Irish population
Source: Annual Congress 2012 - COPD inflammation and genes
Year: 2012
Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy)
Source: Eur Respir J 2006; 28: Suppl. 50, 453s
Year: 2006
Alpha-1 antitrypsin deficiency severity and the risk of COVID-19
Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19
Year: 2021
COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017
Year: 2017
PiS and PiS-plus alleles. The importance of phasing gene variants in Alpha-1 Antitrypsin Deficiency
Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases
Year: 2020
GSTP1 polymorphisms in patients with COPD and alpha-1 antitrypsin deficiency
Source: Eur Respir J 2003; 22: Suppl. 45, 384s
Year: 2003
Prevalence and phenotype of subjects carrying rare variants in Argentina for alpha1-antitrypsin deficiency
Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases
Year: 2017
Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012
Rare SERPINA1 allele Mwhitstable in patients with Alpha1-antitrypsin deficiency
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019
Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested
Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement?
Year: 2020
Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ)
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006
Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population
Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement?
Year: 2020
A new SERPINA-1 missense mutation associated with alpha-1 antitrypsin deficiency and bronchiectasis.
Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases
Year: 2017
Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept